Polycystic Ovary Syndrome has been renamed Polyendocrine Metabolic Ovarian Syndrome after a 14-year global effort led by patients, researchers and clinicians to replace a name that many said missed the real nature of the condition. The new name was published today in The Lancet and is expected to be fully rolled out in the 2028 International Guideline update.
The condition affects 1 in 8 women worldwide, or more than 170 million women, and the renaming campaign drew more than 22,000 survey responses as part of a patient-focused process that included international workshops with patients and multidisciplinary health professionals. More than 50 patient and professional organizations took part in developing the name, and the three-year transition period will be backed by an international education and awareness campaign.
Helena Teede, a leading researcher involved in the work, said there is no increase in abnormal cysts on the ovary in the condition, and that the wide range of symptoms had often been overlooked. The old name, she said, fed the idea that the illness was all about ovarian cysts, when in fact it affects hormones, weight, metabolic health, mental health, skin and the reproductive system.
That misunderstanding has been more than a naming problem. Researchers and advocates say it has helped delay diagnosis, weaken awareness and leave many women with limited care for a condition that has long been dismissed or oversimplified. Teede said a name change was the next critical step after international guidelines had already begun to improve awareness and treatment.
The renaming process was built around principles Teede described as patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and implementation support. She said the change was driven with and for those affected by the condition, and called it a landmark moment that should improve clinical practice and research worldwide.
Over the next three years, doctors, patients and health systems will have to get used to the new terminology while the education campaign works through clinics, professional groups and public messaging. By 2028, the shift is meant to be complete. For millions of women who have spent years being told the name of their condition did not match their symptoms, the new label is meant to do more than describe it better. It is meant to change how seriously it is taken.
